Cost of Revenue Comparison: AbbVie Inc. vs Gilead Sciences, Inc.

Cost of Revenue: A Tale of Two Giants

In the competitive landscape of the pharmaceutical industry, AbbVie Inc. and Gilead Sciences, Inc. have been pivotal players. Over the past decade, from 2014 to 2023, AbbVie has consistently outpaced Gilead in terms of cost of revenue. Starting at $4.4 billion in 2014, AbbVie's cost of revenue surged by over 360% to reach approximately $20.4 billion in 2023. In contrast, Gilead's cost of revenue grew at a more modest pace, increasing by about 72% from $3.8 billion in 2014 to $6.5 billion in 2023.

This stark difference highlights AbbVie's aggressive expansion and investment strategies, particularly in the biologics sector. Meanwhile, Gilead's steadier growth reflects its focus on maintaining efficiency while navigating the challenges of the biotech market. As these two titans continue to evolve, their financial strategies offer valuable insights into the dynamics of the pharmaceutical industry.